

## Data Sharing Statement

Gunduz-Bruce H, Silber C, Kaul I, et al. Trial of SAGE-217 in Patients with Major Depressive Disorder. N Engl J Med. DOI: 10.1056/NEJMoa1815981.

Question	Authors' Response
Will the data collected for your study be made available to others?	Yes
Would you like to offer context for your decision?	—
Which data?	Other
Additional information about data	Data sharing will be consistent with the clinicaltrials.gov data publication policy.
How or where can the data be obtained?	Data sharing will be consistent with the clinicaltrials.gov data publication policy.
When will data availability begin?	Upon completion of Phase 3 Clinical Trials - consistent with clinicaltrials.gov
When will data availability end?	Upon completion of Phase 3 Clinical Trials
Will any supporting documents be available?	—
Which supporting documents?	Other
Additional information about supporting documents	Data sharing will be consistent with the clinicaltrials.gov data publication policy. Primary and secondary endpoints, safety data, and analytic methods (SAP) will be shared, but no SAS codes will be shared.
How or where can supporting documents be obtained?	Data sharing will be consistent with the clinicaltrials.gov data publication policy.
When will supporting documents availability begin?	Upon completion of Phase 3 Clinical Trials - consistent with clinicaltrials.gov
When will supporting documents availability end?	Upon completion of Phase 3 Clinical Trials
To whom will data be available?	clinicaltrials.gov
For what type of analysis or purpose?	Per SAP prespecified methods for summarization and analysis of Patient Disposition, Demographics/baseline characteristics, Primary and Secondary endpoints and safety data.
By what mechanism?	Consistent with ClinicalTrials.gov publication policy
Any other restrictions?	Contact sponsor for additional information/restrictions
Additional information	Contact sponsor for additional information/restrictions

This statement was posted on September 5, 2019, at NEJM.org.